Articles in Category: More News

Reflection on Three Decades of Bioanalysis

News from Tuesday, 21 June 2016.

Reflection on Three Decades of Bioanalysis

Reflection on Three Decades of Bioanalysis

Reflection on Three Decades of Bioanalysis

As founder and CEO of pharm-analyt I go back a long way.

Back in 1975, when I started in the field of bioanalysis, HPLC was brand new technology and UV detectors with fixed wavelength at 254 nm were just becoming the new standard.

In 1978 I obtained a “SP8000”. Being the “Mercedes” among the HPLC-systems, it featured a ternary gradient(!) and a Schoeffel UV detector with variable wavelength! Coming from GC-technology, it was inconceivable, that most any molecule could be determined – not only evaporable molecules or ones made evaporable through derivatisation. Back then, any new molecule determined in plasma was a little sensation, worth a publication!

In the 1990s HPLC-MS systems with ESI (Electrospray Ionisation) and APCI (Atmospheric Pressure Chemical Ionization) became stable enough to be an option for routine work. This is presuming you had the budget, as the cost of technology was outrageously.

I remember, cleaning and establishing “good vacuum” consumed almost half of our time but at least molecules without chromophores and functional groups for derivatisation (e.g. for fluorescence) now became visible in the low ng/mL range.

In the 1980s, a combination of HPLC with electrochemical detectors and glassy carbon, later with porous graphite, was a brilliant option for molecules that can be oxidised.

Then came mass spec technology. The speed of development of HPLC-MS/MS technology since 1995 is staggering! Analyzing peptides with MS has become routine, not to forget PEGylated drugs, hormones and other formerly “terrible” things!

Of course, the femtogram/mL mark in plasma has been passed a long time ago, and we’re ever continuing to shift the limits!

Being part of this dynamic and innovative world of bioanalysis is such a privilege and we are certainly looking forward to the future!

Join us into a new and exciting decade!


Hermann Mascher
CEO and founder of pharm-analyt


News from Thursday, 14 April 2016.

pharm-analyt have recently joined forces with RenaSci (Nottingham) to offer a new service – measurement of drugs and neurotransmitters in the same microdialysate sample.


RenaSci employs dual-probe microdialysis to measure extracellular levels of neurotransmitter in different brain regions of freely-moving rats.

For example, they have recently measured the effects of d-amphetamine 0.5 mg/kg sc on dopamine levels in the nucleus accumbens and on acetylcholine levels in the prefrontal cortex. Microdialysate samples from this study were sent to pharm-analyt for analysis.

The results show an excellent correlation between d-amphetamine concentrations and dopamine levels in the nucleus accumbens and a weaker though still strong relationship between d-amphetamine concentrations and acetylcholine levels in the prefrontal cortex.

pharm-analyt is a fully-independent bioanalytical company based in Baden/Vienna. The company has been measuring small molecules and their metabolites in a variety of biological fluids and tissues for 30 years. For this purpose, they employ state-of-the-art instrumentation mass spectrometry technology. This enables them to quantify drug concentrations in minimal sample volumes with very high sensitivity.

Please click link below to see the data.

The ability to measure drug concentrations and neurotransmitter levels in the same microdialysate sample provides important information regarding the pharmacodynamic-pharmacokinetic properties of the drug.

For further information about this new service please contact us on This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it.

Certificate of Honor to CEO of pharm-analyt

News from Tuesday, 19 January 2016.

Certificate of Honor to CEO of pharm-analyt

We announce with pride that our CEO, Prof. Hermann Mascher received yet another award: The Certificate of Honor of the Austrian Society of Chemistry. 

The certificate recognizes the implementation of his profound chemical knowledge in scientifically sound and technically mature practice. Moreover, he is honored for meeting the international market´s high demands from a business point of view. Last, but not least, he is recognized for his commitment to the concerns of society as well as his employees.





Happy New Year!

News from Thursday, 07 January 2016.

Happy New Year!

Looking back, the last year was a rich year, full of blessings and exciting challenges!

In 2015, a little over half of our work derived from preclinical and clinical bioanalysis for Big Pharma organizations.

But many new projects were added, the majority of those highly innovative Biotech Projects. Often  this very early work has a highly experimental character.
Inhalable drugs have played a significant role again: Analysis at extremely sensitive levels (fg/mL plasma), yet with very low sample volumes (250µL plasma).

Oncology remains a huge topic: Here highly innovative delivery forms are being tried out, but also new drug concepts. Of course these topics require solid assays once in clinical studies.

In 2015 we have invested strongly in our equipment: All HPLC lines were upgraded, most significant was the purchase of another new mass spec line: QTRAP 6500.

We have enjoyed the intensive interactions, the high level discussions and the scouting for solutions of your challenges! May the new year be as exciting!

We are looking forward to yet another year of dialogue and good, long lasting collaborations!

Good success!


Hermann Mascher, CEO pharm-analyt